With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

After hours: November 29 at 4:55 PM EST ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

While this adds competition to a market currently controlled by Eli Lilly and Novo Nordisk, it also reinforces the dominance of the makers of Wegovy and Zepbound. Amgen reported on Tuesday that ...

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist. The Danish pharma ...

Meanwhile Novo Nordisk has also seen its ranking surge up 15 places to third place. The Denmark-headquartered company remains a leader in front-line therapy in type 1 diabetes and has a ...

Synthetic biology is the design and construction of new biological parts, devices, and systems, and the re-design of existing, natural biological systems for useful purposes. Engineered microbes ...